ISIHLUTHULELO-671, KEYTRUDA, Merck, I-NSCLC, I-Pembrolizumab
I-Neoadjuvant/adjuvant pembrolizumab igunyazwe yi-FDA ngomdlavuza wamaphaphu ongewona omncane.
Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment f..
Inkampani Array BioPharma Inc, ibinimetinib, UBraftovi, encorafenib, UMektovi, Pfizer
I-Encorafenib ene-binimetinib igunyazwe yi-FDA yokwelashwa komdlavuza wamaphaphu we-metastatic ongewona omncane ngokuguqulwa kwe-BRAF V600E
I-Food and Drug Administration (i-FDA) igunyaze i-Encorafenib (i-Braftovi, i-Array BioPharma Inc., inkampani ephethwe ngokugcwele ye-Pfizer) kanye ne-binimetinib (Mektovi, Array BioPharma Inc.) ngoNovemba 2023 njengemithi engasetshenziswa ukulungisa inkinga.
Isivivinyo se-ARROW, I-Genentech, I-NSCLC, i-pralsetinib
I-Pralsetinib igunyazwe yi-FDA yomdlavuza wamaphaphu ongewona omncane nge-RET fusion gene
Agasti 2023: I-Pralsetinib (Gavreto, Genentech, Inc.) yanikezwa imvume evamile yi-Food and Drug Administration ezigulini ezikhulile ezinomdlavuza we-RET fusion-positive non-small cell lung cancer (NSCLC), njengoba kunqunywe i-FDA.
FDA, Ukuphathwa Kwezokudla Nezidakamizwa, KEYTRUDA, Merck, I-Pembrolizumab, i-chemotherapy esekelwe e-platinum
I-Pembrolizumab igunyazwe yi-FDA njengokwelashwa kwe-adjuvant kumdlavuza wamaphaphu ongewona omncane.
Feb 2023: Esigabeni IB (T2a 4 cm), isigaba II, noma isigaba IIIA somdlavuza wamaphaphu ongewona omncane, iFood and Drug Administration (FDA) igunyaze i-pembrolizumab (Keytruda, Merck) njengokwelashwa kwe-adjuvant ngemva kokukhishwa kabusha kanye ne-chemoth esekelwe ku-platinum. ..
I-AstraZeneca Pharmaceuticals, i-durvalumab, Imjudo, I-NSCLC, POSEIDON, tremelimumab
I-Tremelimumab igunyazwe yi-FDA ngokuhlanganiswa ne-durvalumab kanye ne-chemotherapy esekelwe ku-platinum yomdlavuza wamaphaphu we-metastatic ongewona omncane.
Novemba 2022: Inhlanganisela ye-tremelimumab (Imjudo, AstraZeneca Pharmaceuticals), i-durvalumab (Imfinzi, AstraZeneca Pharmaceuticals), kanye nokwelashwa ngamakhemikhali okusekelwe ku-platinum kuvunywe yi-Food and Drug Administration kubantu abadala.
Libtayo, I-NCT03409614, I-NSCLC, I-chemotherap esekelwe kwi-platinum, Ama-Regeneron Pharmaceuticals
I-Cemiplimab-rwlc igunyazwe yi-FDA ngokuhlanganiswa ne-chemotherapy-based platinum yomdlavuza wamaphaphu ongewona omncane.
Novemba 2022: Inhlanganisela ye-cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) kanye ne-platinum-based chemotherapy yeziguli zabantu abadala ezinomdlavuza wamaphaphu ongewona omncane omncane (NSCLC) ngaphandle kwe-EGFR, ALK, noma i-ROS1 engavamile.
am-trastuzumab deruxtecan-nxki, Daiichi Sankyo, I-Enhertu
Ukugunyazwa okusheshayo kunikezwa yi-FDA ku-fam-trastuzumab deruxtecan-nxki yomdlavuza wamaphaphu we-HER2-mutant ongewona omncane.
Agasti 2022: Ezigulini ezikhulile ezinomdlavuza we-metastatic non-small cell lung cancer (NSCLC) amathumba azo anokuguqulwa okuholela ekushintsheni kwe-mesenchymal-epithelial (MET) exon 14, njengoba kutholwe ukuhlolwa okugunyazwe yi-FDA, Ukudla.
Capmatinib, I-NCT02414139, Inkampani Novartis Pharmaceuticals Corp, I-NSCLC, I-Tabrecta
I-Capmatinib igunyazelwe umdlavuza wamaphaphu we-metastatic ongewona omncane
Agasti 2022: Ezigulini ezikhulile ezinomdlavuza we-metastatic non-small cell lung cancer (NSCLC) amathumba azo anokuguqulwa okuholela ekushintsheni kwe-mesenchymal-epithelial (MET) exon 14, njengoba kutholwe ukuhlolwa okugunyazwe yi-FDA, Ukudla.
I-BMS, I-CHECKMATE-816, nivolumab, I-NSCLC, I-Opdivo
I-Neoadjuvant nivolumab kanye ne-platinum-doublet chemotherapy igunyazelwe umdlavuza wamaphaphu weselula ongewona omncane.
Mashi 2022: Esimeni se-neoadjuvant, i-FDA igunyaze i-nivolumab (i-Opdivo, i-Bristol-Myers Squibb Company) ngokuhlanganiswa ne-platinum-doublet chemotherapy yeziguli ezikhulile ezinomdlavuza wamaphaphu ongewona omncane (NSCLC).
I-Atezolizumab, I-Genentech, I-NSCLC, I-Tecentriq, Izinhlelo zeVentana Medical, I-VENTANA PD-L1
I-Atezolizumab igunyazwe yi-FDA njengokwelashwa kwe-adjuvant kumdlavuza wamaphaphu ongewona omncane
Nov 2021: I-Food and Drug Administration igunyaze i-atezolizumab (Tecentriq, Genentech, Inc.) yokwelashwa kwe-adjuvant ezigulini ezinomdlavuza wamaphaphu we-cell ongewona omncane wesigaba II kuya ku-III (NSCLC) izimila zazo eziqukethe i-PD-L1 inkulumo.